Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity-Reference-Cited by-同舟云学术

Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity

Published:2024-04-16 Issue:7 Volume:59 Page:910-917
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Liang Emily C.^ORCID,Rejeski Kai,Fei Teng,Albittar Aya,Huang Jennifer J.,Portuguese Andrew J.^ORCID,Wu Qian^ORCID,Raj Sandeep,Subklewe Marion^ORCID,Shouval Roni,Gauthier Jordan

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02278-3.pdf

Reference19 articles.

1. Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805–15. https://ascopubs.org/doi/abs/10.1200/jco.20.01467

2. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://www.thelancet.com/article/S0140673621009338/fulltext

3. Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New Engl J Med. 2021;384:705–16.

4. Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood. 2022;141:1675–84.

5. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill;Current Issues in Molecular Biology;2024-05-15

2. Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb;Pharmaceuticals;2024-05-06